Opus Genetics Inc (IRD) Stock Analysis
Verdict: WATCH (do not buy)
Positive OPGx-BEST1 trial data and cash into 2029 support upside, but heavy insider selling and clinical binary risks demand patience.
Investment score: 45/100
Analysis as of
Is Opus Genetics Inc stock worth reviewing? AI model thesis
Opus Genetics boasts a funded cash runway into 2029 and positive Phase 1/2 OPGx-BEST1 trial data, but heavy net insider selling (18 sells vs 2 buys) and clinical binary risk warrant watching for a stabilized technical re-entry.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 60/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Opus Genetics Inc opportunities and risks
What speaks for IRD
- Phase 1/2 OPGx-BEST1 trial demonstrated positive visual improvements across all 5 Cohort 1 patients with Phase 3 potential dosing in 2027
What speaks against IRD
- Heavy net insider selling with 18 sell transactions versus 2 buys, including major fund liquidations between 4.35 and 5.97
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| IRD | n/a | 35.5x | n/a | 99.9% | -1091.8% | -11.6% |
| EIKN | n/a | 0.0x | n/a | 0.0% | 0.0% | -71.2% |
| FENC | n/a | 6.0x | n/a | 93.7% | -5.5% | -0.6% |
| KYTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -45.4% |
| EBS | n/a | 0.5x | n/a | 49.4% | -23.0% | 24.1% |
| Peer median | n/a | 0.2x | n/a | 24.7% | -2.7% | -23.0% |
Frequently asked questions about Opus Genetics Inc (IRD)
Is IRD stock a good investment?
The cached TradeMates AI model rates Opus Genetics Inc as WATCH (do not buy) with an investment score of 45/100. Opus Genetics boasts a funded cash runway into 2029 and positive Phase 1/2 OPGx-BEST1 trial data, but heavy net insider selling (18 sells vs 2 buys) and clinical binary risk warrant watching for a stabilized technical re-entry. This is algorithmic model output, not personal investment advice.
Is IRD stock a buy?
The TradeMates model verdict for IRD is WATCH (do not buy) with an investment score of 45/100. Treat this as a model signal to review, not a personal buy recommendation.